The prognostic significance of central hemodynamics in patients with cardiac amyloidosis

Amyloid

Volumn 20, Issue 4, 2013, Pages 199-203

  Russo, Christopher ^a   Green, Philip ^a   Maurer, Mathew ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Amyloid; Cardiac; Catheterization; Hemodynamics; Transthyretin

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; PREALBUMIN; TROPONIN I;

ADULT; AGED; ARTERIAL OXYGEN SATURATION; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; COHORT ANALYSIS; DIASTOLIC BLOOD PRESSURE; FEMALE; FORWARD HEART FAILURE; GLOMERULUS FILTRATION RATE; HEART AMYLOIDOSIS; HEART CATHETERIZATION; HEART HEMODYNAMICS; HEART INDEX; HEART MUSCLE BIOPSY; HEART OUTPUT; HEART RIGHT ATRIUM PRESSURE; HEART TRANSPLANTATION; HUMAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY ARTERY OCCLUSION PRESSURE; RETROSPECTIVE STUDY; SURVIVAL; SYSTOLIC BLOOD PRESSURE;

AGED; AMYLOIDOSIS; CARDIOMYOPATHIES; FEMALE; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; PREALBUMIN; PULMONARY WEDGE PRESSURE; RETROSPECTIVE STUDIES;

EID: 84888049142     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2013.821406     Document Type: Article

References (22)

1. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898-909.
2. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009;120:1203-12.
3. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005;12:2047-60.
4. Kholova I, Niessen HW. Amyloid in the cardiovascular system: a review. J Clin Pathol 2005;58:125-33.
5. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis. Am J Hematol 2005;79:319-28.
6. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen 3rd HR, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry based proteomic analysis in clinical biopsy specimens. Blood 2009;114:4957-9.
7. Unverferth DV, Magorien RD, Moeschberger ML, Baker PB, Fetters JK, Leier CV. Factors influencing the one-year mortality of dilated cardiomyopathy. Am J Cardiol 1984;54:147-52.
8. Olofsson BO, Bjerle P, Osterman G. Hemodynamics and angiocardiographic observations in familial amyloidosis with polyneuropathy. Acta Med Scand 1982;212:77-81.
9. Connors LH, Prokaeva T, Lim A, Theberge R, Falk RH, Doros G, Berg A, et al. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J 2009;158:607-14.
10. Lam CS, Borlaug BA, Kane GC, Enders FT, Rodeheffer RJ, Redfield MM. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation 2009;119: 2663-70.
11. Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, Biagini E, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J 2013;34:520-8.
12. Abramov D, Weimer LH, Marboe CC, Shimbo D, King DL, Maurer MS. Absence of heart failure in severe cardiac and autonomic amyloidosis: the essential role of sympathetic activation and venous tone in the development of the congestive heart failure syndrome. Congest Heart Fail 2009;15:288-90.
13. Dubrey SW, Burke MM, Hawkins PN, Banner NR. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant 2004;23: 1142-53.
14. D'Alonzo GE, Bart RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991;115:343-9.
15. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477-82.
16. Morley D, Brozena S. Assessing risk by hemodynamic profile in patients awaiting cardiac transplantation. Am J Cardiol 1994;73: 379-83.
17. Drazner MH, Brown RN, Kaiser PA, Cabuay B, Lewis NP, Semigran MJ, Torre-Amione G, et al. Relationship of right and left-sided filling pressures in patients with advanced heart failure: a 14-year multi-institutional analysis. J Heart Lung Transplant 2012;31:67-72.
18. Testani JM, Khera AV, St. John Sutton MG, Keane MG, Wiegers SE, Shannon RP, Kirkpatrick JN. Effects of right ventricular function and venous congestion on cardiorenal interactions during the treatment of decompensated heart failure. Am J Cardiol 2010; 15:511-16.
19. Colombo PC, Ganda A, Lin J, Onat D, Harxhi A, Iyasere JE, Uriel N, et al. Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Fail Rev 2012;17:177-90.
20. Mullens W, Abraham Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009;53:589-96.
21. Drazner MH, Hellkamp AS, Leier CV, Shah MR, Miller LW, Russell SD, Young JB, et al. Value of clinician assessment of hemodynamics in advanced heart failure: the ESCAPE trial. Circ Heart Fail 2008;1:170-7.
22. Drazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med 2001;345: 574-81.